MediciNova, Inc. Announces Results From A Phase II/III Generalized Anxiety Disorder Trial With MN-305
SAN DIEGO, June 11 /PRNewswire/ -- MediciNova, Inc., a specialty pharmaceutical company that is publicly traded on the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced the results of its Phase II/III randomized, double-blind, placebo-controlled clinical trial of MN-305 in 416 patients with Generalized Anxiety Disorder (GAD). Trends for improvement in all efficacy outcome measures were observed in patients treated with MN-305. Statistically significant improvements in item 1 of the HAM-A (anxious mood) were observed through eight weeks of treatment with MN-305, however, statistical significance on the primary outcome measure of the trial (change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) total score) was not achieved. MN-305 was well tolerated at all doses in the trial.